Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text

Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text

Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

Before the era of targeted therapies, cytokines were the main therapy for metastatic renal cell carcinoma (mRCC). Our aim was to analyze the changes in treatments and overall survival (OS) of all mRCC patients...

Authors:Hannes Jürgens, Kristiina Ojamaa, Helis Pokker, Kaire Innos and Peeter Padrik

Citation:BMC Cancer 2020 20:201

Content type:Research article

Published on: 12 March 2020

• ViewFull Text
 
• ViewPDF